Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE SODIUM PHOSPHATE versus ORTIKOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE SODIUM PHOSPHATE versus ORTIKOS.
DEXAMETHASONE SODIUM PHOSPHATE vs ORTIKOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone sodium phosphate is a glucocorticoid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
ORTIKOS (acalabrutinib) is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). It forms a covalent bond with the active site cysteine residue (Cys481) in BTK, blocking downstream B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
4-20 mg IV or IM every 4-6 hours; for cerebral edema: 10 mg IV followed by 4 mg IM/IV every 6 hours; for shock: 20 mg IV initially then 2-6 mg/kg IV bolus or 40 mg IV every 2-6 hours as needed.
2 mg orally three times daily (total daily dose 6 mg).
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in adults; however, the duration of action extends beyond the plasma half-life due to intracellular receptor-mediated effects.
Terminal half-life of 8 hours (range 6-10) in healthy adults; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug and metabolites accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 30-40%.
Renal (70% unchanged), biliary/fecal (30% as metabolites)
Category D/X
Category C
Corticosteroid
Corticosteroid